Freely Filtered 054: EMPA-Kidney
Listen now
Description
EMPA-Kidney is the last of the big three to report their Kidney Endpoints SGLT2i trial (CREDENCE for Cana, DAPA-CKD for Dapa, and now EMPA-Kidney for Empa) and it answers some questions that, amazingly, were still unanswered.
More Episodes
FSGS is hard and the data sucks. But here comes sparsentan fresh off its win in the PROTECT trial for IgA Nephropathy. Can it pull another rabbit out of the hat for patients that suffer from FSGS or are we doomed to forever treating our patients with Acthar® Gel?
Published 04/22/24
Published 04/22/24
Beep Beep. Hey intern the patient’s blood pressure is 160/95. Do you want to do something.
No. The answer is no.
But honestly we have all been guilted into ordering some clonidine or god forbid some IV hydralazine.
Stop it. Just stop it.
Join the filtrate as we dissect a recent study looking...
Published 03/16/24
Links
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
